Literature DB >> 7510483

Increased antiretroviral antibody reactivity in sera from a defined population of patients with systemic lupus erythematosus. Correlation with autoantibodies and clinical manifestations.

J Blomberg1, O Nived, R Pipkorn, A Bengtsson, D Erlinge, G Sturfelt.   

Abstract

OBJECTIVE: The implied role of retroviruses in the pathogenesis of murine systemic lupus erythematosus (SLE) led us to study antiretroviral antibodies in a population-based SLE cohort.
METHODS: Immunoassays using whole virus and synthetic peptides were performed on sera from 72 patients with SLE and 88 control subjects.
RESULTS: Reactions with whole baboon endogenous virus occurred more frequently in patients with SLE, and correlated with the presence of anti-RNP and anti-Sm. Some retroviral env and gag peptides, several of which were similar to U1 small nuclear RNP, reacted more strongly in patients with SLE, and their presence was correlated with discoid rash, hematologic disorder, and other symptoms.
CONCLUSION: These results provide circumstantial evidence for involvement of retroviruses in the pathogenesis of human SLE; further studies should be carried out using other techniques for measurement of retroviral expression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510483     DOI: 10.1002/art.1780370109

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  18 in total

1.  Urine free light chains in SLE: clonal markers of B-cell activity and potential link to in vivo secreted Ig.

Authors:  J E Hopper; J Golbus; C Meyer; G A Ferrer
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

Review 2.  Systemic lupus erythematosus: Diagnosis and clinical management.

Authors:  Andrea Fava; Michelle Petri
Journal:  J Autoimmun       Date:  2018-11-16       Impact factor: 7.094

3.  Antibody to human endogenous retrovirus peptide in urine of human immunodeficiency virus type 1-positive patients.

Authors:  R W Stevens; A L Baltch; R P Smith; B J McCreedy; P B Michelsen; L H Bopp; H B Urnovitz
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

4.  Epigenetics in systemic lupus erythematosus: leading the way for specific therapeutic agents.

Authors:  Matlock A Jeffries; Amr H Sawalha
Journal:  Int J Clin Rheumtol       Date:  2011-08

5.  Autoantibodies to human endogenous retrovirus-K are frequently detected in health and disease and react with multiple epitopes.

Authors:  C A Herve; E B Lugli; A Brand; D J Griffiths; P J W Venables
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

Review 6.  Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease.

Authors:  H B Urnovitz; W H Murphy
Journal:  Clin Microbiol Rev       Date:  1996-01       Impact factor: 26.132

7.  Reactivity of sera from systemic lupus erythematosus and Sjögren's syndrome patients with peptides derived from human immunodeficiency virus p24 capsid antigen.

Authors:  J E Deas; L G Liu; J J Thompson; D M Sander; S S Soble; R F Garry; W R Gallaher
Journal:  Clin Diagn Lab Immunol       Date:  1998-03

8.  Transposable element dysregulation in systemic lupus erythematosus and regulation by histone conformation and Hsp90.

Authors:  Maurer Kelly; Shi Lihua; Zhang Zhe; Song Li; Paucar Yoselin; Petri Michelle; E Sullivan Kathleen
Journal:  Clin Immunol       Date:  2018-08-24       Impact factor: 3.969

9.  Plasmacytoid dendritic cells in the duodenum of individuals diagnosed with myalgic encephalomyelitis are uniquely immunoreactive to antibodies to human endogenous retroviral proteins.

Authors:  Kenny L De Meirleir; Svetlana F Khaiboullina; Marc Frémont; Jan Hulstaert; Albert A Rizvanov; András Palotás; Vincent C Lombardi
Journal:  In Vivo       Date:  2013 Mar-Apr       Impact factor: 2.155

10.  The Lupus Susceptibility Locus Sgp3 Encodes the Suppressor of Endogenous Retrovirus Expression SNERV.

Authors:  Rebecca S Treger; Scott D Pope; Yong Kong; Maria Tokuyama; Manabu Taura; Akiko Iwasaki
Journal:  Immunity       Date:  2019-01-29       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.